LEVITRA® (ORAL DISPERSIBLE TABLET) - AN INNOVATIVE DRUG FOR THE TREATMENT OF PATIENTS WITH ERECTILE DYSFUNCTION
- Authors: Korneyev I.A1
-
Affiliations:
- Issue: No 2 (2013)
- Pages: 106-111
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279755
- ID: 279755
Cite item
Abstract
The arsenal of professionals providing assistance to men with erectile dysfunction includes a new, mouth dissolving dosage form of the vardenafil — levitra* ODT. This form is effective, safe, and has a higher bioavailability as compared to vardenafil in the form of coated tablets. POTENT I and POTENT II studies revealed that levitra* ODT equally successfully corrects erectile dysfunction in men younger and older than 65 years regardless of concomitant diseases and metabolic disorders: hypertension, diabetes, dyslipidemia. In addition, it was found that this drug helped to successfully carry out sexual intercourse in the first 15 minutes after dosing in 62.5% of patients. This allows to widely recommend levitra * ODT for the treatment of erectile dysfunction in young men and older men.
Keywords
Full Text
References
- Lue T.F., Tanagho E.A. Physiology of erection and pharmacological management of impotence. J. Urol 1987;137(5):829—836.
- Feldman H.A., Goldstein I., Hatzichristou D.G. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol 1994;;151(1):54—61.
- Palmore E.B. Predictors of the longevity difference: a 25-year follow-up. Gerontologist 1982; 22: 513-518.
- Persson G. 5-year mortality in a 70-year-old urban population in relation to psychiatric diagnosis, personality, sexuality, and early parent death. Acta Psychiatr. Scand 1981;64: 244-253.
- Johannes C.B., Araujo A.B., Feldman H.A. et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J. Urol 2000; Feb;163(2):460-463.
- Lewis R.W. Epidemiology of erectile dysfunction. Urol. Clin. North. Am. 2001; May;28(2):209-216
- Nehra A., Jackson G., Miner M. et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012; Aug;87(8):766-78.
- Marshall B.L. Science, medicine and virility surveillance: 'sexy seniors' in the pharmaceutical imagination Sociol. Health Illn. 2010;32(2):211—224.
- Braun M., Wassmer G., Klotz T., et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int. J. Impot. Res. 2000; 12(6):305—311.
- Laumann E.O., Paik A., Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281(6):537—544.
- Аль-Шукри С.Х., Корнеев И.А. Сексуальная функция у мужчин с сопутствующими урологическими заболеваниями. Урология 2005; Т. 3:18—22.
- Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х. и др. Эпидемиологическое исследование распротраненности эректильной дисфункции в Российской Федерации . Русский медицинский журнал. 2012; 20(3): 112—115.
- SatisFACTS. Международний опрос. Байер ХелсКэр, 2011.
- Carvalheira A.A., Pereira N.M., Maroco J. et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J. Sex. Med. 2012;9(9):2361—2369.
- Conaglen H.M., Conaglen J.V. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. J.Sex.Med.2012;9(3):857—865.
- Son H., Park K., Kim S.W. et al. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J. Androl. 2004; 6(2):117—120.
- Zitzmann M., Mattern A., Hanisch J. et al. IPASS: A Study on the Tolerability and Effectiveness of Injectable Testosterone Undecanoate for the Treatment of Male Hypogonadism in a Worldwide Sample of 1,438 Men. J Sex Med. 2013; 10(2):579—588.
- Корнеев И.А. Практические аспекти назначеним заместительной гормональной терапии тестостероном при возрастном андрогенном дефиците у мужчин. Урология. 2012; 5:122—127.
- Hatzichristou D., Rosen R. C., Broderick G. et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004; 1(1):49—57.
- Hanash K.A. Comparative results of goal oriented therapy for erectile dysfunction. J. Urol. 1997; 157(6):2135—38.
- Hackett G.I. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin. Cornerstone 2005;7(1):57—65.
- Jiann B.P., Yu C.C., Su C.C. et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int. J. Impot. Res. 2006; 18(2):146—149.
- Heinig R., Weimann B., Dietrich H. et al. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin. Drug Investig. 2011; 31(1):27—41.
- Ralph D., Eardley I., Kell P. et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int. 2007;100:130—136.
- Eardley I., Lee J.C., Shabsigh R. et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex. Med. 2010;7:244—255.
- Dowson A.J., Charlesworth B.R. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J. Clin. Pract. 2003;57:573—576.
- de Argila C.M., Ponce J., Marquez E. et al. Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease: ACEPTO study. Clin. Drug Investig. 2007;27:765—770.
- Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int. J. Impot. Res. 2004;16(Suppl. 1):S34—S37.
- Sperling H., Debruyne F., Boermans A. et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J. Sex. Med. 2010;7(4 Pt 1):1497—507.
- Gittelman M., McMahon C.G., Rodriguez-Rivera J.A. et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int. J. Clin. Pract. 2010;64(5):594—603.
- Sperling H., Gittelman M., Norenberg C. et al. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J. Sex. Med. 2011; 8(1):261—271.
- Eardley I., Lee J.C., Guay A.T. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. Int. J. Clin. Pract. 2008;62(10):1594—603.
- Debruyne F.M., Gittelman M., Sperling H. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J. Sex. Med. 2011;8(10):2912—2923.
- Ziegler D., Merfort F., van Ahlen H. et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J. Sex. Med. 2006;3:883—891.
- Stief C., Porst H., Saenz De Tejada I. et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int. J. Clin. Pract. 2004;58: 230—239.
- Green R., Hicks R.W. Orally disintegrating vardenafil tablets for the treatment of erectile dysfunction: efficacy, safety, and patient acceptability. Patient Prefer. Adherence. 2011;13;5:181—115.
- Sanford M. Vardenafil orodispersible tablet. Drugs. 2012; 72(1):87—98.